Annette F. Favorite - 30 Aug 2023 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Signature
Ryan Metz as Agent for Annette F. Favorite
Issuer symbol
WST
Transactions as of
30 Aug 2023
Net transactions value
-$662,337
Form type
4
Filing time
01 Sep 2023, 15:46:48 UTC
Previous filing
02 May 2023
Next filing
13 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $166,940 +2,000 +13% $83.47* 16,877 30 Aug 2023 Direct
transaction WST Common Stock Sale $314,788 -760 -4.5% $414.20 16,117 30 Aug 2023 Direct F1
transaction WST Common Stock Sale $514,489 -1,240 -7.7% $414.91 14,877 30 Aug 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Options (Right to buy) Options Exercise $0 -2,000 -19% $0.000000 8,452 30 Aug 2023 Common Stock 2,000 $83.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $413.58 to $414.57, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F2 The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $414.58 to $415.08, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F3 This option is fully vested.